Literature DB >> 9737590

Mechanisms of protection induced by attenuated simian immunodeficiency virus. II. Lymphocyte depletion does not abrogate protection.

R Stebbings1, J Stott, N Almond, R Hull, J Lines, P Silvera, R Sangster, T Corcoran, J Rose, S Cobbold, F Gotch, A McMichael, B Walker.   

Abstract

To determine the role that cellular immune responses play in the protection conferred by vaccination with attenuated SIVmac32H (pC8), we have attempted to deplete macaques of their CD8+ cells prior to challenge with wild-type SIVmac32H (pJ5). In two of four pC8-infected macaques, N109 and N112, a transient partial depletion of CD8+ cells by antibody treatment was achieved. On the day of challenge peripheral CD2+CD4-CD8+ cell counts were reduced by 92 and 95%, respectively, in animals N109 and N112 and their lymph nodes revealed a 46 and 58% reduction, respectively, in CD2+CD4-CD8+ cells. Two other pC8-immunized macaques, N110 and N111, treated in the same way, did not show significant depletion of CD8+ cells. None of these four pC8-immunized animals became infected when challenged with 50 MID50 of pJ5. Treatment of a further four pC8-infected and protected macaques and two naive control animals with Campath-1H antibody successfully depleted peripheral CD3+ cell counts by >99% in all treated animals. Campath-1H depletion resulted in enhanced, longer lasting lymphoid depletion. Yet subsequent challenge with 20 MID50 of pJ5 still failed to infect the pC8-immunized animals. All eight of the naive controls, including two Campath-1H-treated animals, became infected following challenge. In summary, partial depletion of circulating CD8+ cells or total lymphocytes prior to challenge failed to abrogate the protection conferred by vaccination with pC8.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9737590     DOI: 10.1089/aid.1998.14.1187

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  16 in total

1.  A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease.

Authors:  Rama Rao Amara; Kalpana Patel; Genevieve Niedziela; Pragati Nigam; Sunita Sharma; Silvija I Staprans; David C Montefiori; Lakshmi Chenareddi; James G Herndon; Harriet L Robinson; Harold M McClure; Francis J Novembre
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

2.  Persistence of pathogenic challenge virus in macaques protected by simian immunodeficiency virus SIVmacDeltanef.

Authors:  E Khatissian; V Monceaux; M C Cumont; M P Kieny; A M Aubertin; B Hurtrel
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques.

Authors:  Jörn E Schmitz; R Paul Johnson; Harold M McClure; Kelledy H Manson; Michael S Wyand; Marcelo J Kuroda; Michelle A Lifton; Rajinder S Khunkhun; Kimberly J McEvers; Jacqueline Gillis; Michael Piatak; Jeffrey D Lifson; Gudrun Grosschupff; Paul Racz; Klara Tenner-Racz; E Peter Rieber; Kristine Kuus-Reichel; Rebecca S Gelman; Norman L Letvin; David C Montefiori; Ruth M Ruprecht; Ronald C Desrosiers; Keith A Reimann
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  Protective attenuated lentivirus immunization induces SIV-specific T cells in the genital tract of rhesus monkeys.

Authors:  M Genescà; P J Skinner; K M Bost; D Lu; Y Wang; T L Rourke; A T Haase; M B McChesney; C J Miller
Journal:  Mucosal Immunol       Date:  2008-03-05       Impact factor: 7.313

5.  Live attenuated lentivirus infection elicits polyfunctional simian immunodeficiency virus Gag-specific CD8+ T cells with reduced apoptotic susceptibility in rhesus macaques that control virus replication after challenge with pathogenic SIVmac239.

Authors:  Meritxell Genescà; Tracy Rourke; Jun Li; Kristen Bost; Barinderpaul Chohan; Michael B McChesney; Christopher J Miller
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

6.  Extralymphoid CD8+ T cells resident in tissue from simian immunodeficiency virus SIVmac239{Delta}nef-vaccinated macaques suppress SIVmac239 replication ex vivo.

Authors:  Justin M Greene; Jennifer J Lhost; Benjamin J Burwitz; Melisa L Budde; Caitlin E Macnair; Madelyn K Weiker; Emma Gostick; Thomas C Friedrich; Karl W Broman; David A Price; Shelby L O'Connor; David H O'Connor
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

7.  Limited protection from a pathogenic chimeric simian-human immunodeficiency virus challenge following immunization with attenuated simian immunodeficiency virus.

Authors:  M G Lewis; J Yalley-Ogunro; J J Greenhouse; T P Brennan; J B Jiang; T C VanCott; Y Lu; G A Eddy; D L Birx
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

8.  Immunity and protection by live attenuated HIV/SIV vaccines.

Authors:  Dominik Wodarz
Journal:  Virology       Date:  2008-06-30       Impact factor: 3.616

9.  Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239.

Authors:  Helen Horton; Thorsten U Vogel; Donald K Carter; Kathy Vielhuber; Deborah H Fuller; Tim Shipley; James T Fuller; Kevin J Kunstman; Gerd Sutter; David C Montefiori; Volker Erfle; Ronald C Desrosiers; Nancy Wilson; Louis J Picker; Steven M Wolinsky; Chenxi Wang; David B Allison; David I Watkins
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  Limited dissemination of pathogenic SIV after vaginal challenge of rhesus monkeys immunized with a live, attenuated lentivirus.

Authors:  Mars Stone; Zhong-Min Ma; Meritxell Genescà; Linda Fritts; Shelley Blozois; Michael B McChesney; Christopher J Miller
Journal:  Virology       Date:  2009-08-03       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.